Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 30;14(1):180.
doi: 10.1186/s13045-021-01197-w.

Targeting CD47 for cancer immunotherapy

Zhongxing Jiang #  1 , Hao Sun #  2 , Jifeng Yu  3   4 , Wenzhi Tian  5 , Yongping Song  6
Affiliations
Review

Targeting CD47 for cancer immunotherapy

Zhongxing Jiang et al. J Hematol Oncol. .

Abstract

Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 2021, there are a total 23 related therapeutic agents with 46 clinical trials in the NCT registry platform. Among these trials, 29 are in ST, 14 in hematological malignancies and 3 in both solid tumor and hematological malignancy. The ST include gastric cancer, head and neck squamous cell carcinoma and leiomyosarcoma, while the hematological malignancies include non-Hodgkin's lymphoma, acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and chronic myeloid leukemia. Majority of the CD47-related clinical trials are at the early phases, such as 31 at phase I, 14 at phase II and 1 at phase III in the USA and 9, 6, 1, in China, respectively. The targets and spectrums of mechanism of action include 26 with mono-specific and 20 with bi-specific targets in the USA and 13 with mono-specific and 3 with bi-specific targets in China. The new generation CD47 antibodies have demonstrated promising results, and it is highly hopeful that some candidate agents will emerge and make into clinical application to meet the urgent needs of patients.

Keywords: Bi-specific antibody (BsAbs); CD47; Cancer immunotherapy; Clinical trials; Fusion proteins; Monoclonal antibody (mAbs); Signal regulatory protein α (SIRPα).

PubMed Disclaimer

Conflict of interest statement

W.T has ownership interest in ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. All other authors declared no conflicts of interest.

Figures

Fig. 1
Fig. 1
CD47-SIRPα
Fig. 2
Fig. 2
“Don’t eat me” signal versus “eat me” signal
Fig. 3
Fig. 3
Blockades to CD47-SIRPα signal pathway
See this image and copyright information in PMC

References

    1. Arrieta O, Aviles-Salas A, Orozco-Morales M, Hernández-Pedro N, Cardona AF, Cabrera-Miranda L, et al. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. Cancer Med. 2020;9(7):2390–2402. doi: 10.1002/cam4.2882. - DOI - PMC - PubMed
    1. Shi M, Gu Y, Jin K, Fang H, Chen Y, Cao Y, et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunol Immunother CII. 2021;70(7):1831–1840. doi: 10.1007/s00262-020-02806-2. - DOI - PMC - PubMed
    1. Kim H, Jee S, Kim Y, Sim J, Bang S, Son HK, et al. Correlation of CD47 expression with adverse clinicopathologic features and an unfavorable prognosis in colorectal adenocarcinoma. Diagnostics (Basel, Switzerland) 2021;11(4):668. - PMC - PubMed
    1. Imam R, Chang Q, Black M, Yu C, Cao W. CD47 expression and CD163(+) macrophages correlated with prognosis of pancreatic neuroendocrine tumor. BMC Cancer. 2021;21(1):320. doi: 10.1186/s12885-021-08045-7. - DOI - PMC - PubMed
    1. Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci USA. 2017;114(49):E10578–E10585. doi: 10.1073/pnas.1710877114. - DOI - PMC - PubMed

Publication types